Search results for "HEPATITIS"

showing 10 items of 1578 documents

Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease

2020

AbstractObesity-associated inflammation is a key player in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, the exact mechanisms remain incompletely understood. Here we demonstrate that macrophage scavenger receptor 1 (MSR1, CD204) expression is associated with the occurrence of hepatic lipid-laden foamy macrophages and correlates with the degree of steatosis and steatohepatitis in a cohort of 170 NAFLD patients. Mice lacking Msr1 are protected against high fat-cholesterol diet (HFD)-induced metabolic disorder, showing fewer hepatic lipid-laden foamy macrophages, less hepatic inflammation, improved dyslipidemia and glucose tolerance, while showing a change in hepatic …

0303 health sciencesmedicine.medical_specialtyLipopolysaccharidebusiness.industryFatty liverInflammationmedicine.disease3. Good healthMSR1Pathogenesis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologychemistryFibrosisInternal medicineMedicine030211 gastroenterology & hepatologySteatohepatitismedicine.symptomSteatosisbusiness030304 developmental biology
researchProduct

Will the COVID-19 pandemic affect HCV disease burden?

2020

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Pneumonia ViralTime to treatmentAffect (psychology)Antiviral AgentsArticleTime-to-TreatmentBetacoronavirusPandemicHumansMedicineDisease EradicationPandemicsDisease burdenAntiviral AgentDisease EradicationbiologyHepatologyBetacoronaviruPandemicbusiness.industryCoronavirus InfectionSARS-CoV-2GastroenterologyCOVID-19Hepatitis C Chronicbiology.organism_classificationVirologyCoronavirus InfectionsbusinessBetacoronavirusHuman
researchProduct

Compact Cell Imaging Device (CoCID) provides insights into the cellular origins of viral infections

2021

The overall CoCID concept is centred on providing virologists with a next-generation imaging device, which, through increased penetration and depth of focus, as well as through high natural contrast and sensitivity to organelle density (including virus-related organelles), will produce higher-fidelity ultrastructural images of whole intact cells. These insights will, in turn, help increase our understanding of the links between the structural reorganisation of cells and the mechanisms of viral entry, replication, assembly, and egress in cells. CoCID will provide this valuable imaging capability in the form of a compact lab-scale device that will greatly improve the accessibility of soft X-r…

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)viruksetSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CelltutkimuslaitteetBiologymikroskopiawater windowinfektiot03 medical and health sciences0302 clinical medicineherpesvirussoft x-ray microscopymedicinehepatiitti C -virusElectrical and Electronic Engineeringherpesvirukset030304 developmental biology0303 health scienceshepatiitti E -virusSARS-CoV-2röntgensäteilySARS-CoV-2-virusHepatitis Cmedicine.diseaseHepatitis EVirologyAtomic and Molecular Physics and Optics3. Good healthElectronic Optical and Magnetic Materialsmedicine.anatomical_structurekuvantaminenfotoniikka030220 oncology & carcinogenesiscell structure imaginghepatiittiviruksetSoft x-ray microscopyhepatitis Ehepatitis Csolubiologia
researchProduct

Reply to: "Hepatic benefits of HCV cure: Don't forget coagulation!"

2020

2019-20 coronavirus outbreakHepatologyCoronavirus disease 2019 (COVID-19)business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineCoagulation (water treatment)HumansbusinessVirologyBlood CoagulationHepatitis CHumanJournal of hepatology
researchProduct

Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?

2018

Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common cause of chronic liver disease in Western countries, accounting for 20–30% of general population and reaching a prevalence of 55% in patients with type 2 diabetes mellitus (T2DM). Insulin resistance plays a key role in pathogenic mechanisms of NAFLD. Many drugs have been tested but no medications have yet been approved. Antidiabetic drugs could have a role in the progression reduction of the disease. The aim of this review is to summarize evidence on efficacy and safety of antidiabetic drugs in patients with NAFLD. Metformin, a biguanide, is the most frequently used drug in the treatment of T2DM. To date 15 randomized controlled t…

3003medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentlcsh:Medicinelcsh:RS1-441Pharmaceutical Sciencehepatic cirrhosis030209 endocrinology & metabolismReviewChronic liver diseaseGastroenterologylcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicineInsulin resistanceInternal medicineDiabetes mellitusDrug DiscoverymedicineBiguanidebusiness.industryLiraglutideInsulinlcsh:RFatty liverThiazolidinedionenutritional and metabolic diseasesnon-alcoholic fatty liver diseaseLiraglutidemedicine.diseaseMetforminMetforminHepatic cirrhosiMolecular Medicine030211 gastroenterology & hepatologyThiazolidinedionesnon-alcoholic steatohepatitisbusinessNon-alcoholic steatohepatitimedicine.drugPharmaceuticals (Basel, Switzerland)
researchProduct

The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four European countries

2021

Eliminació del VHC; Punt d'equilibri; Infecció d'hepatitis C Eliminación del VHC; Punto de equilibrio; Infección de hepatitis C HCV elimination; Break-even; Hepatitis C infection Background and Aims We assessed the clinical and economic impact of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) in England, Italy, Romania and Spain. Methods An HCV progression Markov model was developed considering DAA eligibility and population data during the years 2015-2019. The period of time to recover the investment in DAAs was calculated as the cost saved by avoiding estimated clinical events for 1000 standardized treated patients. A delayed treatment scenario because of coronavirus di…

:Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Cost Control::Cost Savings [HEALTH CARE]DiseaseHepacivirusmedicine.disease_cause:Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis Viral Human::Hepatitis C [DISEASES]0302 clinical medicineCost of IllnessMedicine:Other subheadings::/therapeutic use [Other subheadings]Economic impact analysisChronicExit strategyevenLiver NeoplasmsHealth services researchhealthInvestment (macroeconomics)Hepatitis C:Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [CHEMICALS AND DRUGS]break‐EnglandItalyHCV elimination030220 oncology & carcinogenesisOriginal Article030211 gastroenterology & hepatologyLiver Disease and Public HealthHumanHepatitis C virusSettore SECS-P/03hepatitis C infectionMedicaments antivírics- Ús terapèuticAntiviral AgentsTime-to-Treatment03 medical and health sciencesbreak-evenHumansbusinessDisease burdenDAAAntiviral Agent:economía y organizaciones para la atención de la salud::economía::costes y análisis de costes::control de costes::ahorro de costes [ATENCIÓN DE SALUD]HepaciviruHepatology:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryRomania:enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis viral humana::hepatitis C [ENFERMEDADES]COVID-19break‐evenDAAsHepatitis C ChronicEstalvi i inversióHcv eliminationCost of IllneSpain:acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos [COMPUESTOS QUÍMICOS Y DROGAS]Communicable Disease ControlVirus de l'hepatitis CbusinessDemography
researchProduct

Campaña sanitaria sobre hepatitis C en un tratamiento con heroína

2008

El Programa de Seguimiento de los pacientes del PEPSA (Programa Experimental de Prescripción de eStupefacientes en Andalucía) es un programa de prescripción y dispensación controlada de opioides (apoyada en la Diacetilmorfina o heroína) dirigido a dependientes a esta sustancia por vía intravenosa que han fracasado en otros recursos. El objetivo de este artículo es exponer el desarrollo de una de las campañas sanitarias que se han llevado a cabo en nuestro centro: la hepatitis C (VHC) y su tratamiento; así mismo, se analiza el impacto que tuvo dicha campaña en los usuarios del centro. Esta campaña sanitaria estuvo dirigida a un grupo de 24 pacientes, todos ellos portadores de anticuerpos de …

:PSICOLOGÍA::Psicofarmacología [UNESCO]:PSICOLOGÍA [UNESCO]UNESCO::PSICOLOGÍAHeroína PSP-PEPSA reducción de daños educación para la salud hepatitis C y tratamiento con heroínaUNESCO::PSICOLOGÍA::Psicofarmacología
researchProduct

Screening y selección de pacientes candidatos a un tratamiento frente al VHC en usuarios de drogas

2009

El screening de la hepatitis C está indicado en cualquier población en la cual hay más riesgo del esperado para detectar la infección. Una de estas poblaciones es la formada por los usuarios de drogas intravenosas en cualquier periodo de sus vidas o la de los que inhalan cocaína. Los programas de Metadona son situaciones ideales para realizar este screening, reducir el riesgo de infección y aconsejar hábitos de vida saludables. Virtualmente todos los individuos que han estado expuestos al VHC, tendrán un test de anticuerpos positivo; los individuos que han resuelto la infección tendrán anticuerpos frente al virus pero no virus detectable. Sólo los test virológicos puede hacer esta determina…

:PSICOLOGÍA::Psicofarmacología [UNESCO]Drogadicción Hepatitis C Diagnóstico Selección para tratamiento antiviral.:PSICOLOGÍA [UNESCO]UNESCO::PSICOLOGÍAUNESCO::PSICOLOGÍA::Psicofarmacología
researchProduct

Análisis coste-utilidad de la triple terapia con telaprevir en pacientes con hepatitis C no tratados previamente

2014

Introducción: En España, con una prevalencia del 2,5%, la hepatitis C (VHC) se asocia a una elevada morbi-mortalidad. El tratamiento combinado de telaprevir y peginterferon/ribavirina ([T/PR]) es eficaz en pacientes con VHC-G1. El objetivo primario de este estudio fue evaluar la relación coste-utilidad (RCUI) de [T/PR] versus peginterferon alfa 2a/ribavirina ([PR]) en pacientes naïve VHC-G1, según el grado de fibrosis y bajo la perspectiva del sistema sanitario español. Metodología: La eficacia y la incidencia de efectos adversos (EAs) se obtuvieron de los estudios ADVANCE y OPTIMIZE. La estimación de los costes de monitorización, de manejo de EAs y de la enfermedad por estados de salud (€,…

; Genotype 1lcsh:RRibavirinalcsh:Medicinelcsh:RS1-441Genotype 1Hepatitis CTelaprevirGenotipo 1lcsh:Pharmacy and materia medicaCoste-utilidadCost-effectivenessPeginterferon alfa 2aRibavirinehealth care economics and organizationsFarmacia Hospitalaria
researchProduct

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.

2022

Funder: European Commission

ALTtype 2 diabetes mellitusROC receiving operator characteristicaspartate aminotransferaseHSDLDL low-density lipoproteinUHPLC ultrahigh-performance liquid chromatographyROCHCCNon-alcoholic steatohepatitisGCPCANASHGastroenterology2-HB 2-hydroxybutanoic acid; 3-HB 3-hydroxybutanoic acid; ALT alanine aminotransferase; AST aspartate aminotransferase; CE cholesterol ester; Cer ceramide; FFA free fatty acid; FLIP Fatty Liver Inhibition of Progression; Fibrosis; GC gas chromatography; HCC hepatocellular carcinoma; HSD honest significant difference; LC lipid cluster; LDL low-density lipoprotein; LM lipid and metabolite; LMC lipid metabolite and clinical variable; LPC lysophosphatidylcholine; Lipidomics; Mass spectrometry; Metabolomics; NAFL non-alcoholic fatty liver; NAFLD non-alcoholic fatty liver disease; NAS NASH activity score; NASH non-alcoholic steatohepatitis; NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network; NRR non-rejection rate; Non-alcoholic steatohepatitis; PC(O) ether PC; PC phosphatidylcholine; PCA principal component analysis; PE phosphatidylethanolamine; QTOFMS quadrupole-time-of-flight mass spectrometry; ROC receiving operator characteristic; SAF steatosis activity and fibrosis; SM sphingomyelin; T2DM type 2 diabetes mellitus; TG triacylglycerol; UHPLC ultrahigh-performance liquid chromatographySAFSAF steatosis activity and fibrosisLM lipid and metabolitehonest significant differenceHSD honest significant differenceTG triacylglycerolnon-rejection ratecholesterol esterPCPEGC gas chromatographyfree fatty acidFLIPNASH non-alcoholic steatohepatitisNIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkBIOMARKERST2DMPE phosphatidylethanolamineLDLlipidNAFLDFFA free fatty acid2-HBMetabolomicsNAFL non-alcoholic fatty liverLMCphosphatidylcholineScience & TechnologySM sphingomyelinGastroenterology & HepatologyMass spectrometryactivitynutritional and metabolic diseasesT2DM type 2 diabetes mellitusACIDSreceiving operator characteristicdigestive system diseasesquadrupole-time-of-flight mass spectrometryLC lipid clusterlow-density lipoproteinNAS2-HB 2-hydroxybutanoic acidNAS NASH activity scoreQTOFMSether PCNRRSCORING SYSTEMprincipal component analysisgas chromatographyLC2-hydroxybutanoic acidPROGRESSIONAST aspartate aminotransferaseLMPC phosphatidylcholinePC(O)MARKERSUHPLCsteatosisTOOLImmunology and AllergyINSULIN-RESISTANCECerSMFatty Liver Inhibition of Progressionhepatocellular carcinoma2-HB 2-hydroxybutanoic acid NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network NRR non-rejection rate Non-alcoholic steatohepatitis PC(O) ether PC PC phosphatidylcholine PCA principal component analysis PE phosphatidylethanolamine QTOFMS quadrupole-time-of-flight mass spectrometry ROC receiving operator characteristic SAF steatosis activity and fibrosis SM T2DM type 2 diabetes mellitus TG triacylglycerol UHPLC ultrahigh-performance liquid chromatographyultrahigh-performance liquid chromatographyCELPC3-HBNAFLnon-alcoholic fatty liverTGtriacylglycerolNRR non-rejection rateLife Sciences & BiomedicineNAFLD non-alcoholic fatty liver diseaseFLIP Fatty Liver Inhibition of Progressionalanine aminotransferasemetaboliteCer ceramideCE cholesterol estersphingomyelinlysophosphatidylcholineand fibrosisALT alanine aminotransferaseInternal MedicineceramideNational Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkAST3-HB 3-hydroxybutanoic acidQTOFMS quadrupole-time-of-flight mass spectrometryPCA principal component analysisLPC lysophosphatidylcholineHepatologynon-alcoholic fatty liver diseaseand clinical variablePC(O) ether PC3-hydroxybutanoic acidFibrosisNASH activity scoreNIDDK NASH-CRNlipid clusterlipid and metabolitephosphatidylethanolamineLipidomicsLMC lipid metabolite and clinical variableFFAHCC hepatocellular carcinomaJHEP reports : innovation in hepatology
researchProduct